Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Integrating Genetic Variants into Hypertrophic Cardiomyopathy Risk Stratification: A Quantitative and Comparative Analysis
Session:
SESSÃO DE POSTERS 57 - MIOCARDIOPATIA HIPERTRÓFICA
Speaker:
Inês Miranda
Congress:
CPC 2025
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
17. Myocardial Disease
Subtheme:
17.2 Myocardial Disease – Epidemiology, Prognosis, Outcome
Session Type:
Cartazes
FP Number:
---
Authors:
Inês Pereira de Miranda; Filipa Gerardo; Carolina Pereira Mateus; Mara Sarmento; Rodrigo Brandão; João Bicho Augusto
Abstract
<p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:14px"><span style="color:#000000"><strong>Background: </strong>Hypertrophic cardiomyopathy (HCM) is often associated with pathogenic or likely pathogenic (P/LP) genetic variants and variants of unknown significance (VUS). The prognostic value of gene-positive status, especially in the context of ESC Sudden Cardiac Death (SCD) risk scoring, remains underexplored.</span></span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:14px"><span style="color:#000000"><strong>Objective: </strong>To evaluate (1) the prevalence of P/LP variants and VUS in a cohort of HCM patients, and (2) the prognostic role of these variants individually or integrated into existing risk stratification models.</span></span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:14px"><span style="color:#000000"><strong>Methods: </strong>Single-center prospective cohort of 92 HCM patients who underwent genetic testing between January 2018 and November 2024. The prevalence of P/LP variants and VUS was determined. Our primary endpoint was a composite of cardiovascular events that included admission for heart failure, ventricular fibrillation/tachycardia, cardiac syncope, cardiovascular cardiac death, myocardial infarction, ischemic stroke and/or complete heart block. A combined prognostic model was built by adding P/LP status to the ESC SCD risk score; logistic regression was performed to determine the optimal weight for P/LP status. Discrimination performance was assessed using C-statistics for the ESC SCD model alone and the combined model. Integrated discrimination improvement (IDI) and calibration analysis were conducted to assess the additional value of genetic data. The net clinical benefit of the baseline and combined models was compared across thresholds using decision curve analysis (DCA).</span></span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:14px"><span style="color:#000000"><strong>Results: </strong>A total of 71 HCM patients (65±12 years, 49.3% female) were suitable for analysis, 77.5% septal HCM, 15.5% apical and 7% mixed disease. A mutation was observed in 49.3% of the patients, 66% of which were LP/P variants, 34% were VUS. The most frequent mutations involved the gene <em>MYBPC3</em>. Primary endpoint was met in 57.7% of patients. Mean ESC SCD risk scores were 3.40% for pathogenic, 2.33% for VUS, and 2.52% for gene-negative individuals (p > 0.05 for all comparisons). The baseline ESC SCD model achieved a C-statistic of 0.569; including a weighted P/LP variable (weight = 0.036) resulted in a C-statistic of 0.567. IDI for the weighted model was 0.001, with a modest improvement for events (+1.2%) and a decline for non-events (-1.1%). Calibration analysis showed minimal differences between the weighted model and ESC SCD risk score alone. Decision curve analysis highlighted marginal improvement in net benefit at lower risk thresholds when genetic data were included.</span></span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:14px"><span style="color:#000000"><strong>Conclusions: </strong>Genetic testing reveals a prevalence of P/LP variants in 1 every 3 HCM patients, but provides limited independent prognostic value. The ESC SCD risk score remains the dominant predictor of cardiovascular events, with minor incremental benefits from incorporating genetic pathogenicity. Larger studies are needed to validate these findings and explore advanced integration of genetic data into clinical practice.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site